Aurora Cannabis Q4 Earnings Call Highlights

1 hour ago 3

MarketBeat

Thu, June 11, 2026 astatine 8:04 AM CDT 7 min read

Profit from the Green Wave: Top Cannabis Stocks to Watch

Aurora Cannabis (NASDAQ:ACB) reported a stronger fiscal 2026 show than it had forecast, driven by maturation successful planetary aesculapian cannabis, portion informing that fiscal 2027 volition beryllium a "reset year" arsenic Canadian aesculapian reimbursement changes measurement connected gross and margins.

Executive Chairman and CEO Miguel Martin said fiscal 2026 was "a beardown twelvemonth for Aurora," with nett gross meaningfully supra the company's outlook and adjusted EBITDA supra the midpoint of its guidance range. He said the results reflected Aurora's absorption connected aesculapian cannabis successful nationally ineligible markets and disciplined fiscal management.

→ Cybersecurity Earnings: 1 AI Standout and 2 Stocks Under Pressure

The Cannabis Sector: Profitability Takes Center Stage

For the fiscal twelvemonth ended March 31, 2026, Aurora reported nett gross of CAD 321 million, up 11% from the anterior twelvemonth and CAD 8 cardinal supra the apical extremity of its guided range. Martin said astir 55% of nett gross was generated extracurricular Canada. Adjusted gross borderline roseate to 64%, and adjusted EBITDA accrued 32% twelvemonth implicit twelvemonth to CAD 54 million. The institution ended the twelvemonth with CAD 165 cardinal successful currency and currency equivalents and nary debt.

Medical Cannabis Drives Fourth-Quarter Growth

CFO Simona King said fourth-quarter nett gross roseate 10% twelvemonth implicit twelvemonth to CAD 84.8 million, driven by 14% maturation successful planetary aesculapian cannabis revenue, including a 19% summation internationally. She said 58% of full nett gross successful the 4th was generated extracurricular Canada.

→ Planet Labs: Coming Back Down to Earth

Aurora Cannabis Earnings Reveal a Turning Tide for the Stock

Medical cannabis nett gross roseate 14% to CAD 77.1 million, a grounds for combined Canadian and planetary nett revenue, according to King. Medical cannabis represented 91% of full nett revenue, up from 88% successful the prior-year quarter. Adjusted gross borderline for aesculapian cannabis was 66%, down from the anterior twelvemonth owed to income of lower-margin products and strategical terms reductions successful definite markets.

Adjusted EBITDA for the 4th was CAD 9.2 million, portion adjusted nett income was CAD 5.6 million, compared with CAD 16.3 cardinal successful the prior-year period. King said the diminution successful adjusted nett income chiefly reflected higher adjusted SG&A, little overseas speech gains and little involvement income.

→ What's Make of Macy's: Berkshire Hathaway's Latest Buy

Consumer cannabis nett gross fell to CAD 3.6 cardinal from CAD 8.2 cardinal arsenic the institution shifted angiosperm toward higher-margin aesculapian cannabis and moved to upwind down parts of the Canadian user segment.

Read Entire Article